

Advancements in acquisition hardware has reduced the size and cost restraints on this system, making it more readily adaptable to clinical settings and low resource facilities. As digital hardware solutions progress, the tradeoffs in performance that had to be sacrificed can be slowly regained and optical biopsy solutions such as DRSi can be further miniaturized.

By expanding the nature of DRS from a point probing tool to an imaging platform, the potential of this instrument as a viable skin cancer diagnostic tool is enhanced.

Acknowledgments

This research was supported by the National Institutes of Health (R01CA132032-02W1 and R21 EB015892) and the Texas Higher Education Coordinating Board.